metronidazole + nystatin + fluocinolone acetonide

**metronidazole + nystatin + fluocinolone acetonide** is a pharmaceutical combination intended for vaginal application, formulated to treat mixed vaginal infections involving anaerobic bacteria and fungi. **Metronidazole** is a nitroimidazole antibiotic and antiprotozoal agent that disrupts DNA synthesis in bacteria and protozoa, leading to cell death, primarily targeting anaerobic organisms and protozoal parasites. **Nystatin** is a polyene antifungal that binds to ergosterol in fungal cell membranes, increasing permeability and causing leakage of essential cell components, specifically effective against Candida species. **Fluocinolone acetonide** is a synthetic glucocorticoid corticosteroid that acts as an anti-inflammatory and immunosuppressive agent by modulating transcription of genes responsive to corticosteroids, thereby reducing inflammation, irritation, and edema. This combination, although used in some compounded or regional products, is designed to provide comprehensive therapy for mixed vaginal infections involving bacterial vaginosis, vulvovaginal candidiasis, and associated symptoms such as inflammation and itching. Metronidazole and nystatin combinations are widely indicated and studied for bacterial vaginosis and vulvovaginal candidiasis, while fluocinolone acetonide is added to address inflammatory symptoms, though its use in vaginal preparations is less common and primarily intended for severe or persistent inflammation. The product is applied topically (usually as ovules, pessaries, or cream) into the vagina, allowing localized delivery and reduced systemic exposure. Developers of this exact triple combination are not widely established; such combinations are primarily available as compounded pharmacy products or regional formulations.

Brand names

vagitrol v

Other names

metronidazole + nystatin + fluocinolone acetonide